Detalhe da pesquisa
1.
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
Blood
; 137(8): 1019-1023, 2021 02 25.
Artigo
Inglês
| MEDLINE | ID: mdl-33167024
2.
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial.
Haematologica
; 107(12): 2859-2869, 2022 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35615931
3.
Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study.
Haematologica
; 106(3): 701-707, 2021 03 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32241844
4.
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
Blood
; 129(7): 846-854, 2017 02 16.
Artigo
Inglês
| MEDLINE | ID: mdl-27932374
5.
Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study.
Haematologica
; 102(8): 1368-1377, 2017 08.
Artigo
Inglês
| MEDLINE | ID: mdl-28522576
6.
Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study.
Haematologica
; 103(8): e356-e359, 2018 08.
Artigo
Inglês
| MEDLINE | ID: mdl-29519866
7.
Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide.
Haematologica
; 103(4): e143-e146, 2018 04.
Artigo
Inglês
| MEDLINE | ID: mdl-29269520
8.
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.
Blood Adv
; 7(15): 3936-3945, 2023 08 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37026799
9.
Clinical presentation, outcome, and prognostic markers in patients with intravascular large B-cell lymphoma, a lymphoma study association (LYSA) retrospective study.
Cancer Med
; 11(19): 3602-3611, 2022 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35538643
10.
Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia.
Blood Adv
; 5(9): 2438-2446, 2021 05 11.
Artigo
Inglês
| MEDLINE | ID: mdl-33961019
11.
Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years.
Cancers (Basel)
; 13(18)2021 Sep 07.
Artigo
Inglês
| MEDLINE | ID: mdl-34572728
12.
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
Lancet Haematol
; 6(9): e470-e479, 2019 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-31324600
13.
Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.
Clin Cancer Res
; 25(22): 6606-6613, 2019 11 15.
Artigo
Inglês
| MEDLINE | ID: mdl-31292142
14.
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.
J Clin Oncol
; 35(3): 298-305, 2017 Jan 20.
Artigo
Inglês
| MEDLINE | ID: mdl-28095277
15.
Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study.
Haematologica
; 91(8): 1027-32, 2006 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-16885042
16.
Two new cases of familial hairy cell leukemia associated with HLA haplotypes A2, B7, Bw4, Bw6.
Leuk Lymphoma
; 46(2): 243-5, 2005 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-15621808
17.
Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia.
Blood
; 106(3): 1063-6, 2005 Aug 01.
Artigo
Inglês
| MEDLINE | ID: mdl-15840695
18.
Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia.
Blood
; 103(1): 363-5, 2004 Jan 01.
Artigo
Inglês
| MEDLINE | ID: mdl-12969985